Skip to main content
NovaBay Pharmaceuticals, Inc. logo

NovaBay Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NBY ISIN · US66987P2011 LEI · 549300D5U7PQPNEX8Q38 US Manufacturing
Open in API
Filings indexed 1,026 across all filing types
Latest filing 2025-03-07 Regulatory Filings
Country US United States of America
Listing US NBY

About NovaBay Pharmaceuticals, Inc.

https://novabay.com/

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes scientifically-created and clinically-proven products for the eyecare, skincare, and wound care markets. The company's core technology is a proprietary, stable formulation of hypochlorous acid. Its leading product is Avenova®, an antimicrobial lid and lash solution available over-the-counter for eye hygiene. In the wound care sector, NovaBay manufactures and sells products under the NeutroPhase® and PhaseOne® brands, which utilize its hypochlorous acid technology to aid in cleansing and debridement. The company focuses on providing accessible, problem-solving solutions for improved well-being.

Recent filings

Filing Released Lang Actions
FORM DEFA14A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NovaBay Pharmaceuticals, Inc. It details the entry into a material definitive agreement with Lucid Capital Markets for financial advisory services related to exploring a potential business combination or strategic alternatives. The document includes descriptions of the engagement agreement terms, references to a preliminary proxy statement on Schedule 14A, and mentions a forthcoming definitive proxy statement. It also includes a press release as an exhibit. The content focuses on corporate actions and strategic alternatives rather than financial results, management changes, or proxy solicitations themselves. The document is not a proxy statement but references one to be filed. It is not an earnings release, annual report, or other financial report. The primary purpose is to announce the engagement agreement and related strategic evaluation, which fits best under the category of Regulatory Filings (RNS) as a general regulatory announcement that does not fit more specific categories like M&A filings or proxy solicitations. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-03-07 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes the company's entry into a material definitive agreement with a financial advisor to explore potential business combinations and strategic alternatives, including mergers and partnerships. It also references a preliminary proxy statement and a forthcoming special meeting of stockholders. The document includes a press release and an engagement agreement as exhibits. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual/interim report. The primary focus is on announcing a material agreement and strategic update, which fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories. The document length is over 12,000 characters, so it is not a brief announcement of a report publication (RPA). Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-03-07 English
FORM PRE 14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically a Preliminary Proxy Statement for a Special Meeting of Stockholders of NovaBay Pharmaceuticals, Inc. It includes detailed information about proposals to be voted on, including a dissolution proposal and an adjournment proposal. The document contains extensive information about the meeting, voting procedures, background on the company, and the plan of dissolution. The presence of the term 'Proxy Statement' and the SEC form PRE 14A clearly identifies this as proxy solicitation material. Proxy Statements are classified under Proxy Solicitation & Information Statement (PSI). The document is not an Annual Report, Earnings Release, or any other financial report type, but a solicitation for shareholder votes on corporate actions.
2025-02-18 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-07 English
FORM DEFA14A
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NovaBay Pharmaceuticals, Inc. It details the submission of matters to a vote of security holders at a Special Meeting, specifically the voting results on proposals related to the liquidation and dissolution of the company. The document includes detailed voting results, descriptions of the proposals, and plans for future shareholder meetings and proxy statements. It is not a full annual or quarterly report, nor is it an earnings release or audit report. It is also not a proxy solicitation itself but references proxy statements to be filed. The document primarily announces the results of shareholder votes and related corporate actions. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is substantial and contains detailed voting results, not just a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is DVA with high confidence.
2025-02-04 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by NovaBay Pharmaceuticals, Inc. It details the submission of matters to a vote of security holders, specifically the results of a special meeting regarding proposals including the liquidation and dissolution of the company. The document includes detailed voting results and descriptions of the proposals, as well as plans for future shareholder meetings and proxy statements. It is not a full annual or quarterly report, nor is it an earnings release or audit report. It is also not a proxy solicitation itself but references proxy statements to be filed. The document primarily reports the official results of shareholder votes on specific proposals at a special meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length and detail support this classification with high confidence.
2025-02-04 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.